Mar 5, 2018
Santhera's Raxone shows no efficacy benefit in MS study - https://wp.me/p8XyML-kHw - #Benefit, #Efficacy, #MS, #Raxone, #Santheras, #Shows, #Study
seen from United States
seen from China
seen from China
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from China
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
Santhera's Raxone shows no efficacy benefit in MS study - https://wp.me/p8XyML-kHw - #Benefit, #Efficacy, #MS, #Raxone, #Santheras, #Shows, #Study
Neuropatia ottica ereditaria, in commercio il Raxone
Neuropatia ottica ereditaria, in commercio il Raxone
Neuropatia ottica ereditaria Leber (Lhon), autorizzata l’immissione in commercio in Europa per il Raxone. Il farmaco, prodotto da Santhera è la prima terapia approvata per questa patologia: senza trattamento i pazienti erano destinati alla cecità nel giro di pochi mesi Liestal (Svizzera), 10/09/2015 – I pazienti europei affetti da neuropatia ottica ereditaria di Leber (LHON) hanno finalmente a…
View On WordPress